Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) Research & Development (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Research & Development data on record, last reported at $49.2 million in Q1 2026.

  • On a quarterly basis, Research & Development rose 60.76% to $49.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $176.3 million, a 40.75% increase, with the full-year FY2025 number at $157.7 million, up 26.65% from a year prior.
  • Research & Development reached $49.2 million in Q1 2026 per OLMA's latest filing, up from $43.2 million in the prior quarter.
  • Over the last five years, Research & Development for OLMA hit a ceiling of $49.2 million in Q1 2026 and a floor of $16.0 million in Q1 2022.
  • A 5-year average of $29.4 million and a median of $29.1 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 127.15% in 2022, then tumbled 33.51% in 2023.
  • Tracing OLMA's Research & Development over 5 years: stood at $21.6 million in 2022, then increased by 19.87% to $25.9 million in 2023, then rose by 24.84% to $32.3 million in 2024, then skyrocketed by 33.81% to $43.2 million in 2025, then grew by 13.91% to $49.2 million in 2026.
  • Business Quant data shows Research & Development for OLMA at $49.2 million in Q1 2026, $43.2 million in Q4 2025, and $40.0 million in Q3 2025.